Fulton Bank N.A. Boosts Holdings in Sanofi $SNY

Fulton Bank N.A. boosted its holdings in Sanofi (NASDAQ:SNY) by 29.4% in the 1st quarter, HoldingsChannel reports. The firm owned 64,573 shares of the company’s stock after purchasing an additional 14,658 shares during the quarter. Fulton Bank N.A.’s holdings in Sanofi were worth $3,111,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Raymond James Financial Inc. boosted its position in shares of Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after acquiring an additional 2,635,867 shares during the last quarter. Capital Research Global Investors bought a new stake in Sanofi in the 4th quarter valued at $79,960,000. Morgan Stanley increased its holdings in Sanofi by 20.4% in the 4th quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after acquiring an additional 1,540,271 shares during the last quarter. Franklin Resources Inc. lifted its stake in Sanofi by 29.7% in the 4th quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after purchasing an additional 1,168,339 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Sanofi by 422.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock valued at $50,165,000 after purchasing an additional 859,246 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SNY shares. Citigroup restated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Morgan Stanley set a $52.00 price target on Sanofi in a report on Friday, May 1st. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Finally, BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Stock Performance

Sanofi stock opened at $41.63 on Thursday. The company’s 50-day moving average price is $43.84 and its 200-day moving average price is $45.90. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company has a market cap of $100.93 billion, a PE ratio of 11.63, a price-to-earnings-growth ratio of 1.05 and a beta of 0.35. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were paid a dividend of $2.4225 per share. The ex-dividend date of this dividend was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. Sanofi’s payout ratio is presently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.